 |
|
|
|
|
Registration for SIO's 2020 Annual Scientific Meeting is officially OPEN! Be the first of your colleagues to register for the premier interventional oncology (IO) meeting where you'll experience innovative programming, connect with a global community of IO luminaries, experience New Orleans, and much more!
Register Today and Get More for Less
Bundling your registration with SIO membership and other add-ons ensures that you’ll get the most out of your meeting registration – for a reduced cost! Even more, you'll save $125+ when you register by 30 November 2019. Visit the SIO website to view registration packages and rates, and to register.
REGISTER!
SIO 2019 presented some of the industry's best programming to date, and SIO2020 is building off that momentum to offer even more! Register today and take advantage of:
Innovative Programming
SIO2020 will feature brand-new, cutting-edge presentations, including:
- Pioneers and New Frontiers (see where IO started and where it's going)
- Hypoxia
- Complex IO: Decision-Making
- Outpatient IO
- Sarcoma and Soft Tissue
- Venous Interventions
- Oligometastatic Disease and Oligoprogression
- SIO Meets the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR)
... while also featuring standard scientific topics that it's known for, such as:
- Hepatocellular Carcinoma
- Renal
- SIO Supported Research
- How I Do It Video Session
- Colorectal Liver Metastases
- Comparative Effectiveness
- Tumor Boards
Share your science with hundreds of professionals in the global interventional oncology community: Submit an abstract to present at SIO2020, taking place 31 January–3 February 2020 in New Orleans, Louisiana!
 Abstracts due 9 September 2019 at 11:59pm ET.
Why Submit?
Presenting your abstract at the SIO2020 annual meeting helps you gain exposure for your work and contributes to the breadth of scientific research at the forefront of the interventional oncology field.
SIO is accepting abstracts on the following topics:
- Basic Science
- Genitourinary
- Guidance & Targeting
- HCC
- Imaging
|
- Liver Metastases
- Technology
- Thoracic
- Education
- Other
|
Accepted abstract authors will be recognized on the Society of Interventional Oncology website and in the SIO mobile app. All accepted abstracts will also be eligible for a scientific award to be presented at SIO2020!
Visit the SIO website to learn more, to submit your abstracts, and to register for the meeting.
 The field of Interventional Oncology, as well as the continued success of Society of Interventional Oncology (SIO), is dependent on individuals like you. SIO membership not only illustrates dedication to the mission of the society, but to the continued growth and success of the field of IO.
Your membership secures your place among the most influential minds in this emerging specialty and gives you access to New Member Benefits!
Join Now!
Oncology
This study evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN). Researchers enrolled 84 u-HCC cases treated with TKIs including LEN from March 2018 to January 2019. Clinical findings at introduction of the initial TKI were retrospectively evaluated. READ MORE
| Promoted by |
|
|
|
 |
Clinics and Research in Hepatology and Gastroenterology
Microvascular invasion (MVI) has been associated with a poor prognosis for hepatocellular carcinoma (HCC) patients. This study aimed to evaluate the efficacy and safety of adjuvant transarterial chemoembolization (TACE) after curative hepatectomy for HCC with MVI. The study concluded that adjuvant TACE after hepatectomy is effective and safe for patients with HCC accompanied by MVI. However, the benefit of adjuvant TACE in patients who have HCC with a diameter greater than 5 cm is not clear. Further randomized controlled studies are warranted to test these conclusions. READ MORE |
|
The Clinical Respiratory Journal
VTE due to lung cancer has been sufficiently studied, nevertheless, little is known regarding the discrepancy of clinical characteristics and predictive factors amongst different presentations of VTE due to lung cancer. This study was designed to investigate the distinction of clinical characteristics and predictive factors amongst different presentations of VTE due to lung cancer. READ MORE
American Journal of Clinical Oncology
Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase one study was initiated to establish the recommended phase two dose of sorafenib combined with vorinostat in patients with unresectable hepatocellular carcinoma. Although some patients had durable disease control, the addition of vorinostat to sorafenib led to toxicities in most patients, requiring dose modifications that prevented determination of the recommended phase two dose. The combination is not recommended for further exploration with this vorinostat schedule in this patient population. READ MORE |
| Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year. Read more |
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure |
|
|
|
|
Expert Review of Molecular Diagnostics
Circulating tumor cell (CTC) counts represent an attractive strategy for monitoring response to therapy in patients with advanced non-small cell lung cancer (NSCLC). Changes in the CTCs number during the treatment have been proposed as a predictive biomarker of response to both chemotherapy and targeted therapies. Profiling of CTCs might also allow the assessment of the dynamics of predictive biomarkers such as EGFR, ALK, ROS1, and PD-L1, and provide relevant information in patients progressing on treatment with targeted agents including immunotherapeutics. READ MORE |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
